Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors

Clin Chem Lab Med. 2021 Feb 5;59(7):1181-1200. doi: 10.1515/cclm-2020-1685. Print 2021 Jun 25.

Abstract

Despite advances in screening and therapeutics cancer continues to be one of the major causes of morbidity and mortality worldwide. The molecular profile of tumor is routinely assessed by surgical or bioptic samples, however, genotyping of tissue has inherent limitations: it represents a single snapshot in time and it is subjected to spatial selection bias owing to tumor heterogeneity. Liquid biopsy has emerged as a novel, non-invasive opportunity of detecting and monitoring cancer in several body fluids instead of tumor tissue. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), RNA (mRNA and microRNA), microvesicles, including exosomes and tumor "educated platelets" were recently identified as a source of genomic information in cancer patients which could reflect all subclones present in primary and metastatic lesions allowing sequential monitoring of disease evolution. In this review, we summarize the currently available information concerning liquid biopsy in breast cancer, colon cancer, lung cancer and melanoma. These promising issues still need to be standardized and harmonized across laboratories, before fully adopting liquid biopsy approaches into clinical practice.

Keywords: cancer biomarkers; circulating cell-free DNA and RNA; circulating tumor DNA; circulating tumor cells; exosomes; liquid biopsy.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Circulating Tumor DNA*
  • Humans
  • Liquid Biopsy
  • MicroRNAs* / genetics
  • Neoplastic Cells, Circulating*

Substances

  • Biomarkers, Tumor
  • Circulating Tumor DNA
  • MicroRNAs